Homology Medicines, Inc. – LSE:0T6G.L
Homology Medicines stock price today
Homology Medicines stock price monthly change
Homology Medicines stock price quarterly change
Homology Medicines stock price yearly change
Homology Medicines key metrics
Market Cap | 44.70M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -25.13 |
Revenue | N/A |
EBITDA | -78.61M |
Income | -83.08M |
Revenue Q/Q | -100% |
Revenue Y/Y | -546.00% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHomology Medicines stock price history
Homology Medicines stock forecast
Homology Medicines financial statements
| Jun 2023 | 354K | -35.04M | -9899.44% |
|---|---|---|---|
| Sep 2023 | 0 | -32.95M | |
| Dec 2023 | -14.66M | -16.11M | 109.94% |
| Mar 2024 | 0 | 1.02M |
| Dec 2023 | -14.66M | -16.11M | 109.94% |
|---|---|---|---|
| Mar 2024 | 0 | 1.02M | |
| Sep 2025 | -15.15M | -2.64M | 17.44% |
| Dec 2025 | -15.22M | -2.64M | 17.35% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 169337000 | 49.96M | 29.5% |
|---|---|---|---|
| Sep 2023 | 140063000 | 51.85M | 37.02% |
| Dec 2023 | 306119000 | 233.12M | 76.16% |
| Mar 2024 | 152334000 | 103.56M | 67.99% |
| Mar 2023 | -26.05M | 31.37M | 150K |
|---|---|---|---|
| Jun 2023 | -23.66M | 61.00M | 2K |
| Sep 2023 | -24.94M | -22.76M | 18K |
| Dec 2023 | -21.57M | 31.71M | 14K |
Homology Medicines alternative data
| Aug 2023 | 92 |
|---|---|
| Sep 2023 | 92 |
| Oct 2023 | 92 |
| Nov 2023 | 92 |
| Dec 2023 | 92 |
| Jan 2024 | 92 |
| Feb 2024 | 92 |
| Mar 2024 | 7 |
| Apr 2024 | 7 |
| May 2024 | 37 |
| Jun 2024 | 39 |
| Jul 2024 | 39 |
Homology Medicines other data
| Patent |
|---|
Application Filling date: 10 Dec 2021 Issue date: 30 Jun 2022 |
Application Filling date: 5 Nov 2021 Issue date: 26 May 2022 |
Application Filling date: 5 Nov 2021 Issue date: 26 May 2022 |
Application Filling date: 9 Sep 2021 Issue date: 7 Apr 2022 |
Application Filling date: 27 May 2021 Issue date: 23 Dec 2021 |
Application Filling date: 5 Apr 2021 Issue date: 25 Nov 2021 |
Application Filling date: 13 Jan 2021 Issue date: 26 Aug 2021 |
Application Filling date: 19 Oct 2020 Issue date: 6 May 2021 |
Application Filling date: 19 Mar 2020 Issue date: 8 Oct 2020 |
Application Filling date: 24 Feb 2020 Issue date: 17 Sep 2020 |
| Insider | Compensation |
|---|---|
Dr. Arthur O. Tzianabos (1963) Pres, Chief Executive Officer & Director | $845,780 |
| Dr. Albert Seymour Ph.D. (1968) Chief Scientific Officer | $581,070 |
| Mr. W. Bradford Smith (1956) Chief Financial Officer, Treasurer & Sec. | $552,760 |
| Ms. Theresa McNeely Chief Communications Officer & Patient Advocate | |
Ms. Melissa Gelormini Vice President of HR | |
| Mr. Timothy P. Kelly Chief Technical Operations Officer | |
Mr. Michael Blum M.B.A. Senior Vice President of Commercial | |
Dr. Gabriel M. Cohn M.B.A., M.D. Chief Medical Officer | |
Dr. Paul Alloway J.D., Ph.D. Senior Vice President & Gen. Counsel | |
Dr. Saswati Chatterjee Co-Founder & Chair of Scientific Advisory Board |
-
What's the price of Homology Medicines stock today?
One share of Homology Medicines stock can currently be purchased for approximately $3.65.
-
When is Homology Medicines's next earnings date?
Unfortunately, Homology Medicines's (0T6G.L) next earnings date is currently unknown.
-
Does Homology Medicines pay dividends?
No, Homology Medicines does not pay dividends.
-
How much money does Homology Medicines make?
Homology Medicines has a market capitalization of 44.70M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 307.33% to -6.65M US dollars.
-
What is Homology Medicines's stock symbol?
Homology Medicines, Inc. is traded on the LSE under the ticker symbol "0T6G.L".
-
What is Homology Medicines's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Homology Medicines?
Shares of Homology Medicines can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Homology Medicines's key executives?
Homology Medicines's management team includes the following people:
- Dr. Arthur O. Tzianabos Pres, Chief Executive Officer & Director(age: 62, pay: $845,780)
- Dr. Albert Seymour Ph.D. Chief Scientific Officer(age: 57, pay: $581,070)
- Mr. W. Bradford Smith Chief Financial Officer, Treasurer & Sec.(age: 69, pay: $552,760)
- Ms. Theresa McNeely Chief Communications Officer & Patient Advocate
- Ms. Melissa Gelormini Vice President of HR
- Mr. Timothy P. Kelly Chief Technical Operations Officer
- Mr. Michael Blum M.B.A. Senior Vice President of Commercial
- Dr. Gabriel M. Cohn M.B.A., M.D. Chief Medical Officer
- Dr. Paul Alloway J.D., Ph.D. Senior Vice President & Gen. Counsel
- Dr. Saswati Chatterjee Co-Founder & Chair of Scientific Advisory Board
-
Is Homology Medicines founder-led company?
Yes, Homology Medicines is a company led by its founder Dr. Saswati Chatterjee.
-
How many employees does Homology Medicines have?
As Jul 2024, Homology Medicines employs 39 workers, which is 457% more then previous quarter.
-
When Homology Medicines went public?
Homology Medicines, Inc. is publicly traded company for more then 6 years since IPO on 4 Oct 2018.
-
What is Homology Medicines's official website?
The official website for Homology Medicines is homologymedicines.com.
-
Where are Homology Medicines's headquarters?
Homology Medicines is headquartered at One Patriots Park, Bedford, MA.
-
How can i contact Homology Medicines?
Homology Medicines's mailing address is One Patriots Park, Bedford, MA and company can be reached via phone at +7 813017277.
Homology Medicines company profile:
Homology Medicines, Inc.
homologymedicines.comLSE
42
Medical - Pharmaceuticals
Healthcare
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Bedford, MA 01730
:
ISIN: US4380831077
:
